Biosimilars Following a positive European Medicines Agency recommendation in May this year, the European Commission has now approved Shanghai Henlius Biotech and Accord Healthcare Zercepac, a biosimilar of Roche’s Herceptin (trastuzumab), for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer and previously untreated HER2-positive metastatic gastric cancer. 30 July 2020